A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy

RecruitingOBSERVATIONAL

Enrollment

10,000

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions

Type 2 Diabetes

Trial Locations (2)

RECRUITING

Andong Hospital, Andong

NOT_YET_RECRUITING

Konkuk University medical center, Seoul